{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:16:28Z","timestamp":1791918988302,"version":"4.3.4"},"reference-count":84,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["onlinecjc.ca","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Cardiology"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.cjca.2016.02.078","type":"journal-article","created":{"date-parts":[[2016,4,9]],"date-time":"2016-04-09T15:21:13Z","timestamp":1460215273000},"page":"831-841","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":175,"title":["Canadian Cardiovascular Society Guidelines for Evaluation and Management of Cardiovascular Complications of Cancer Therapy"],"prefix":"10.1016","volume":"32","author":[{"given":"Sean A.","family":"Virani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Dent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Brezden-Masley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margot K.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davinder S.","family":"Jassal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Lemieux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Paterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igal A.","family":"Sebag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Simmons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Sulpher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kishore","family":"Thain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paaldinesh","family":"Thavendiranathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason R.","family":"Wentzell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nola","family":"Wurtele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc Andr\u00e9","family":"C\u00f4t\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nowell M.","family":"Fine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haissam","family":"Haddad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley D.","family":"Hayley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Hopkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil A.","family":"Joy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Rayson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellamae","family":"Stadnick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn","family":"Straatman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cjca.2016.02.078_bib1","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1158\/1055-9965.EPI-12-1356","article-title":"Cancer survivors in the United States: prevalence across the survivorship trajectory and implications for care","volume":"22","author":"de Moor","year":"2013","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.cjca.2016.02.078_bib2","doi-asserted-by":"crossref","first-page":"R64","DOI":"10.1186\/bcr2901","article-title":"Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort study","volume":"13","author":"Patnaik","year":"2011","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.cjca.2016.02.078_bib3","doi-asserted-by":"crossref","first-page":"4952","DOI":"10.1200\/JCO.2006.08.0499","article-title":"Overall survival and cause-specific mortality of patients with stage T1a,bN0M0 breast carcinoma","volume":"25","author":"Hanrahan","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cjca.2016.02.078_bib4","first-page":"190","article-title":"The prevention of cardiovascular disease in cancer survivors","volume":"39","author":"Daher","year":"2012","journal-title":"Tex Heart Inst J"},{"key":"10.1016\/j.cjca.2016.02.078_bib5","first-page":"1326","article-title":"Adding \u201cvalue\u201d to clinical practice guidelines","volume":"53","author":"McCormack","year":"2007","journal-title":"Can Fam Physician"},{"key":"10.1016\/j.cjca.2016.02.078_bib6","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/j.jacc.2007.06.037","article-title":"Early breast cancer therapy and myocardial injury","volume":"50","author":"Jones","year":"2007","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2016.02.078_bib7","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1053\/j.seminoncol.2013.01.008","article-title":"Strategies to prevent and treat cardiovascular risk in cancer patients","volume":"40","author":"Cardinale","year":"2013","journal-title":"Semin Oncol"},{"key":"10.1016\/j.cjca.2016.02.078_bib8","doi-asserted-by":"crossref","first-page":"3673","DOI":"10.1200\/JCO.2013.49.3205","article-title":"Modifiable risk factors and major cardiac events among adult survivors of childhood cancer","volume":"31","author":"Armstrong","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cjca.2016.02.078_bib9","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1056\/NEJMsa060185","article-title":"Chronic health conditions in adult survivors of childhood cancer","volume":"355","author":"Oeffinger","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2016.02.078_bib10","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1158\/1055-9965.EPI-09-0555","article-title":"Cardiovascular risk factors in adult survivors of pediatric cancer \u2013 a report from the Childhood Cancer Survivor Study","volume":"19","author":"Meachem","year":"2010","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.cjca.2016.02.078_bib11","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1002\/cncr.11407","article-title":"Congestive heart failure in patients treated with doxorubicin. A retrospective analysis of three trials","volume":"97","author":"Swain","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.cjca.2016.02.078_bib12","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(07)60028-2","article-title":"HERA study team 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial","volume":"369","author":"Smith","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2016.02.078_bib13","doi-asserted-by":"crossref","first-page":"7820","DOI":"10.1200\/JCO.2005.13.300","article-title":"Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment","volume":"23","author":"Ewer","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cjca.2016.02.078_bib14","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1200\/JCO.2007.13.5467","article-title":"Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial","volume":"26","author":"Perez","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cjca.2016.02.078_bib15","doi-asserted-by":"crossref","first-page":"3859","DOI":"10.1200\/JCO.2006.09.1611","article-title":"Trastuzumab-associated cardiac adverse effects in the Herceptin adjuvant trial","volume":"25","author":"Suter","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cjca.2016.02.078_bib16","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1002\/cncr.10854","article-title":"Trastuzumab-associated cardiotoxicity","volume":"95","author":"Keefe","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.cjca.2016.02.078_bib17","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1200\/JCO.2008.17.2627","article-title":"American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants","volume":"27","author":"Hensley","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 7","key":"10.1016\/j.cjca.2016.02.078_bib18","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1093\/annonc\/mds293","article-title":"Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines","volume":"23","author":"Curigliano","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cjca.2016.02.078_bib19","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1161\/CIRCULATIONAHA.110.992230","article-title":"Effects of novel angiogenesis inhibitors for the treatment of cancer on the cardiovascular system: focus on hypertension","volume":"124","author":"Nazer","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2016.02.078_bib20","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.cjca.2014.02.011","article-title":"Hypertension due to antiangiogenic cancer therapy with vascular endothelial growth factor inhibitors: understanding and managing a new syndrome","volume":"30","author":"Small","year":"2014","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2016.02.078_bib21","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1200\/JCO.2007.14.9930","article-title":"Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study","volume":"26","author":"Saltz","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cjca.2016.02.078_bib22","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","article-title":"Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Grothey","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2016.02.078_bib23","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1200\/JCO.2008.19.5511","article-title":"Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III Treatment Approaches in Renal Cancer Global Evaluation trial","volume":"27","author":"Escudier","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cjca.2016.02.078_bib24","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/S0140-6736(11)61613-9","article-title":"Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial","volume":"378","author":"Rini","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2016.02.078_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fonc.2015.00039","article-title":"Radiation-induced heart disease: pathologic abnormalities and putative mechanisms","volume":"5","author":"Taunk","year":"2015","journal-title":"Front Oncol"},{"key":"10.1016\/j.cjca.2016.02.078_bib26","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1016\/j.jacc.2013.01.090","article-title":"Cardiac complications of thoracic irradiation","volume":"61","author":"Jaworski","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2016.02.078_bib27","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1200\/JCO.2009.27.2757","article-title":"Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials","volume":"28","author":"Choueiri","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cjca.2016.02.078_bib28","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.echo.2014.07.012","article-title":"Expert consensus for multi-modality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"27","author":"Plana","year":"2014","journal-title":"J\u00a0Am Soc Echocardiogr"},{"key":"10.1016\/j.cjca.2016.02.078_bib29","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1111\/j.1540-8175.2011.01490.x","article-title":"Prevalence of abnormal echocardiographic findings in cancer patients: a retrospective evaluation of echocardiography for identifying cardiac abnormalities in cancer patients","volume":"28","author":"Daher","year":"2011","journal-title":"Echocardiography"},{"key":"10.1016\/j.cjca.2016.02.078_bib30","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1038\/sj.bjc.6604909","article-title":"Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring","volume":"100","author":"Jones","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1016\/j.cjca.2016.02.078_bib31","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1093\/eurheartj\/ehi666","article-title":"Rapid online quantification of left ventricular volume from real-time three-dimensional echocardiographic data","volume":"27","author":"Jacobs","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2016.02.078_bib32","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1093\/oxfordjournals.eurheartj.a015273","article-title":"Accuracy and reproducibility of biplane two-dimensional echocardiographic measurements of left ventricular dimensions and function","volume":"18","author":"Otterstad","year":"1997","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2016.02.078_bib33","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jacc.2012.09.035","article-title":"Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy","volume":"61","author":"Thavendiranathan","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2016.02.078_bib34","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.1200\/JCO.2011.40.3584","article-title":"Screening adult survivors of childhood cancer for cardiomyopathy: comparison of echocardiography and cardiac magnetic resonance imaging","volume":"30","author":"Armstrong","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cjca.2016.02.078_bib35","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1067\/mje.2000.103597","article-title":"Feasibility and accuracy of left ventricular volumes and ejection fraction determination by fundamental, tissue harmonic, and intravenous contrast imaging in difficult-to-image patients","volume":"13","author":"Yu","year":"2000","journal-title":"J\u00a0Am Soc Echocardiogr"},{"key":"10.1016\/j.cjca.2016.02.078_bib36","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.echo.2008.09.009","article-title":"American Society of Echocardiography consensus statement on the clinical applications of ultrasonic contrast agents in echocardiography","volume":"21","author":"Mulvagh","year":"2008","journal-title":"J\u00a0Am Soc Echocardiogr"},{"key":"10.1016\/j.cjca.2016.02.078_bib37","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1053\/euhj.2000.2011","article-title":"Comparison of left ventricular ejection fraction and volumes in heart failure by echocardiography, radionuclide ventriculography and cardiovascular magnetic resonance; are they interchangeable?","volume":"21","author":"Bellenger","year":"2000","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2016.02.078_bib38","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/0735-1097(94)00506-L","article-title":"Correspondence of left ventricular ejection fraction determinations from two-dimensional echocardiography, radionuclide angiography and contrast cineangiography","volume":"25","author":"Naik","year":"1995","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2016.02.078_bib39","doi-asserted-by":"crossref","first-page":"3429","DOI":"10.1200\/JCO.2009.26.7294","article-title":"Role of three-dimensional echocardiography in breast cancer: comparison with two-dimensional echocardiography, multiple-gated acquisition scans, and cardiac magnetic resonance imaging","volume":"28","author":"Walker","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cjca.2016.02.078_bib40","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1532-429X-10-5","article-title":"Delayed contrast enhancement cardiac magnetic resonance imaging in trastuzumab induced cardiomyopathy","volume":"10","author":"Fallah-Rad","year":"2008","journal-title":"J\u00a0Cardiovasc Magn Reson"},{"key":"10.1016\/j.cjca.2016.02.078_bib41","first-page":"70","article-title":"Trastuzumab-induced cardiac dysfunction: A \u2018dual-hit\u2019","volume":"16","author":"Zeglinski","year":"2011","journal-title":"Exp Clin Cardiol"},{"key":"10.1016\/j.cjca.2016.02.078_bib42","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/jmri.1052","article-title":"Measurement of left ventricular dimensions and function in patients with dilated cardiomyopathy","volume":"13","author":"Strohm","year":"2001","journal-title":"J\u00a0Magn Reson Imaging"},{"key":"10.1016\/j.cjca.2016.02.078_bib43","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1161\/CIRCIMAGING.113.000899","article-title":"Cardiac MRI in the assessment of cardiac injury and toxicity from cancer chemotherapy: a systematic review","volume":"6","author":"Thavendiranathan","year":"2013","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.cjca.2016.02.078_bib44","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0002-9149(02)02381-0","article-title":"Comparison of interstudy reproducibility of cardiovascular magnetic resonance with two-dimensional echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy","volume":"90","author":"Grothues","year":"2002","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cjca.2016.02.078_bib45","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1016\/j.jacc.2010.11.063","article-title":"The utility of cardiac biomarkers, tissue velocity and strain imaging and cardiac MRI in predicting early left ventricular dysfunction in patients with HER-2 positive breast cancer treated with adjuvant Trastuzumab therapy","volume":"57","author":"Fallah-Rad","year":"2011","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2016.02.078_bib46","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1161\/CIRCIMAGING.112.973321","article-title":"Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab","volume":"5","author":"Sawaya","year":"2012","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.cjca.2016.02.078_bib47","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1016\/j.jacc.2014.01.073","article-title":"Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review","volume":"63","author":"Thavendiranathan","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2016.02.078_bib48","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1093\/annonc\/mdf170","article-title":"Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy","volume":"13","author":"Cardinale","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cjca.2016.02.078_bib49","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1373\/49.2.248","article-title":"Minor increases in plasma troponin I predict decreased left ventricular ejection fraction after high-dose chemotherapy","volume":"49","author":"Sandri","year":"2003","journal-title":"Clin Chem"},{"key":"10.1016\/j.cjca.2016.02.078_bib50","first-page":"309","article-title":"Assessment of anthracycline-induced cardiotoxicity with biochemical markers","volume":"29","author":"Horacek","year":"2007","journal-title":"Exp Oncol"},{"key":"10.1016\/j.cjca.2016.02.078_bib51","doi-asserted-by":"crossref","first-page":"3910","DOI":"10.1200\/JCO.2009.27.3615","article-title":"Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation","volume":"28","author":"Cardinale","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cjca.2016.02.078_bib52","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.jacc.2013.10.061","article-title":"Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab","volume":"63","author":"Ky","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2016.02.078_bib53","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1016\/j.jacc.2013.02.072","volume":"61","author":"Bosch","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2016.02.078_bib54","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1093\/ehjci\/jet159","article-title":"Use of speckle strain to assess left ventricular responses to cardiotoxic chemotherapy and cardioprotection","volume":"15","author":"Negishi","year":"2014","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.cjca.2016.02.078_bib55","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1016\/j.ejca.2013.04.030","article-title":"Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: a systematic review and meta-analysis","volume":"49","author":"Kalam","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.cjca.2016.02.078_bib56","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.jacc.2014.06.1167","article-title":"Prevention of anthracycline-induced cardiotoxicity","volume":"64","author":"Vejpongsa","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2016.02.078_bib57","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1186\/1471-2407-11-318","volume":"11","author":"Pituskin","year":"2011","journal-title":"BMC Cancer"},{"key":"10.1016\/j.cjca.2016.02.078_bib58","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1159\/000343622","article-title":"Rationale and design of the prevention of cardiac dysfunction during an adjuvant breast cancer therapy (PRADA) trial","volume":"123","author":"Heck","year":"2012","journal-title":"Cardiology"},{"key":"10.1016\/j.cjca.2016.02.078_bib59","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1093\/ehjci\/jet123","article-title":"Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography","volume":"14","author":"Lancellotti","year":"2013","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.cjca.2016.02.078_bib60","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa1209825","article-title":"Risk of ischemic heart disease in women after radiotherapy for breast cancer","volume":"368","author":"Darby","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2016.02.078_bib61","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.radonc.2013.07.017","article-title":"Left-sided breast cancer radiotherapy with and without breath-hold: does IMRT reduce the cardiac dose even further?","volume":"108","author":"Mast","year":"2013","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.cjca.2016.02.078_bib62","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.ijrobp.2013.12.035","article-title":"SPECT analysis of cardiac perfusion changes after whole-breast\/chest wall radiation therapy with or without active breathing coordinator: results of a randomized phase 3 trial","volume":"88","author":"Zellars","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.cjca.2016.02.078_bib63","doi-asserted-by":"crossref","first-page":"4100","DOI":"10.1200\/JCO.2005.05.1037","article-title":"Late cardiac mortality and morbidity in early-stage breast cancer patients after breast-conservation treatment","volume":"24","author":"Harris","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cjca.2016.02.078_bib64","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.cjca.2015.02.016","article-title":"The 2015 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension","volume":"31","author":"Daskalopoulou","year":"2015","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2016.02.078_bib65","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.cjca.2012.01.021","article-title":"Focussed 2012 Update of the Canadian Cardiovacsular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate\/rhythm control","volume":"28","author":"Skanes","year":"2012","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2016.02.078_bib66","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/bjc.2014.564","article-title":"QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors","volume":"112","author":"Ghatalia","year":"2015","journal-title":"Br J Cancer"},{"key":"10.1016\/j.cjca.2016.02.078_bib67","doi-asserted-by":"crossref","first-page":"7045","DOI":"10.1158\/1078-0432.CCR-09-1521","article-title":"Electrocardiographic characterization of the QTc interval in patients with advanced solid tumors: pharmacokinetic-pharmacodynamic evaluation of sunitinib","volume":"15","author":"Bello","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cjca.2016.02.078_bib68","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1056\/NEJMoa022147","article-title":"Risk stratification in the long-QT syndrome","volume":"348","author":"Priori","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2016.02.078_bib69","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1016\/j.ejca.2013.03.004","article-title":"Use of raltitrexed as an alternative to 5-fluorouracil and capecitabine in cancer patients with cardiac history","volume":"49","author":"Kelly","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.cjca.2016.02.078_bib70","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1517\/14740330902733961","article-title":"Fluoropyrimidine-associated cardiotoxicity: revisited","volume":"8","author":"Saif","year":"2009","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.cjca.2016.02.078_bib71","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1016\/j.jacc.2014.09.016","volume":"64","author":"Amsterdam","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2016.02.078_bib72","first-page":"1249","article-title":"Capecitabine cardiotoxicity-case reports and literature review","volume":"55","author":"Manojlovic","year":"2008","journal-title":"Hepatogastroenterology"},{"key":"10.1016\/j.cjca.2016.02.078_bib73","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1038\/sj.bjc.6600967","article-title":"Prophylactic options in patients with 5-fluorouracil-associated cardiotoxicity","volume":"88","author":"Cianci","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1016\/j.cjca.2016.02.078_bib74","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1056\/NEJMoa071028","article-title":"Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer","volume":"357","author":"Vermorken","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2016.02.078_bib75","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.cjca.2014.05.013","article-title":"Canadian Cardiovascular Society guidelines for the diagnosis and management of stable ischemic heart disease","volume":"30","author":"Mancini","year":"2014","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2016.02.078_bib76","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0828-282X(09)70019-4","article-title":"Canadian Cardiovascular Society Working Group: providing a perspective on the 2007 focused update of the American College of Cardiology and American Heart Association 2004 guidelines for the management of ST elevation myocardial infarction","volume":"25","author":"Welsh","year":"2009","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2016.02.078_bib77","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.echo.2013.07.005","article-title":"Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography","volume":"26","author":"Lancellotti","year":"2013","journal-title":"J\u00a0Am Soc Echocardiogr"},{"key":"10.1016\/j.cjca.2016.02.078_bib78","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0828-282X(06)70237-9","article-title":"Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006: diagnosis and management","volume":"22","author":"Arnold","year":"2006","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2016.02.078_bib79","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1152\/japplphysiol.00677.2010","article-title":"Exercise protects against doxorubicin-induced oxidative stress and proteolysis in skeletal muscle","volume":"111","author":"Smuder","year":"2011","journal-title":"J\u00a0Appl Physiol"},{"key":"10.1016\/j.cjca.2016.02.078_bib80","doi-asserted-by":"crossref","unstructured":"Jones L, Dolinsky VW, Haykowsky MJ, et\u00a0al. Effects of aerobic training to improve cardiovascular function and prevent cardiac remodeling after cytotoxic therapy in early breast cancer. Presented at: 102nd Annual Meeting of the American Association of Cancer Research, April 2-6, 2011; Orlando, FL.","DOI":"10.1158\/1538-7445.AM2011-5024"},{"key":"10.1016\/j.cjca.2016.02.078_bib81","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1161\/CIRCHEARTFAILURE.112.000055","article-title":"Cardioprotective effect of \u03b2-adrenoreceptor blockade in patients with breast cancer undergoing chemotherapy: follow-up study of heart failure","volume":"6","author":"Seicean","year":"2013","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cjca.2016.02.078_bib82","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1161\/CIRCULATIONAHA.106.635144","article-title":"Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition","volume":"114","author":"Cardinale","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2016.02.078_bib83","first-page":"246","article-title":"Onco-cardiology: the time has come","volume":"38","author":"Yeh","year":"2011","journal-title":"Tex Heart Inst J"},{"key":"10.1016\/j.cjca.2016.02.078_bib84","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.cjca.2015.06.019","article-title":"The Canadian Cardiovascular Society Heart Failure Companion: bridging guidelines to your practice","volume":"32","author":"Howlett","year":"2016","journal-title":"Can J Cardiol"}],"container-title":["Canadian Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X16300046?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X16300046?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T07:38:19Z","timestamp":1567755499000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0828282X16300046"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":84,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["S0828282X16300046"],"URL":"https:\/\/doi.org\/10.1016\/j.cjca.2016.02.078","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.726473736.793550714","asserted-by":"object"}]},"ISSN":["0828-282X"],"issn-type":[{"value":"0828-282X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Canadian Cardiovascular Society Guidelines for Evaluation and Management of Cardiovascular Complications of Cancer Therapy","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cjca.2016.02.078","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}